Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS. The company’s lead compound, BXQ-350, is a novel S1P modulator. With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company. To learn more about Bexion Pharmaceuticals, please visit Bexionpharma.com or contact Margaret van Gilse at (859) 446-7386 or mvangilse@bexionpharma.com.
Location: United States, Kentucky, Covington
Member count: 11-50
Total raised: $16.6M
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | Keyhorse C... | keyhorse.v... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 29.04.2019 | Series B | $16.6M | - | - |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 15.04.2023 | Bexion Pha... | COVINGTON, Ky., April 15, 2023... | - | - | einpresswi... |
| 02.02.2022 | Bexion Pha... | COVINGTON, Ky., Feb. 2, 2022 /... | - | - | marketscre... |
| 09.04.2021 | New Segmen... | JUPITER, Fla. (PRWEB) April 09... | - | - | prweb.com/... |
| 22.02.2021 | Bexion Pha... | COVINGTON, Ky., Feb. 22, 202... | - | - | prnewswire... |
| 17.11.2020 | Bexion Pha... | COVINGTON, Ky., Nov. 17, 202... | - | - | prnewswire... |